Announced Sun, 19 Jul · 16:18 IST
Q1 FY27: Revenue up 28% YoY to Rs 697 cr, margins dip 90 bps
Investor Communications View source PDF
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.4%1-day move
₹530.05
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-3.4-6.2-7.2-7.6-1.5—————
Up moveDown movePending
AI summary
Rossari Biotech posted Q1 FY27 revenue of Rs 697.2 cr, up 28% YoY, driven by broad-based 28% growth across HPPC, TSC, and AHN segments. EBITDA rose 19% to Rs 80.6 cr, though margin fell 90 bps to 11.6%. PAT grew 4.5% to Rs 35.1 cr. Company commissioned a new 5,000 MTPA blending facility in Thailand and sold its Andheri office as part of non-core asset monetisation.
Likely market impact
Strong top-line growth but margin compression; Thailand facility and non-core asset sales signal focus on efficiency and global expansion.